PD-1 blockade alone has no visible effects on wild-type B16 tumor growth, which is in line with earlier reports showing B16 tumor cells are of poor immunogenicity and refractory to PD-1-PD-L1 checkpoint blockade (Fig. 7b)64,65. This evidence concerns the gene CD274 and neoplasm.